Key facts
- MyOme’s last known valuation is $186.5M (Dec 2025).
- It has raised $99.9M; the latest was Later Stage VC ($63.5M) in Dec 2025.
- Notable investors include Sequoia Capital, Founders Fund, Samsung NEXT Ventures, Norwest, HOF Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for MyOme
- ·The full record, as it builds
Funding rounds
No funding rounds for MyOme are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MyOme
Developer of a genetic testing technology designed to provide comprehensive health insights through whole genome sequencing. The company's platform offers detailed reports on disease risk and medication response, includes independent physician reviews and genetic counselling, and utilizes advanced technologies to ensure ongoing updates, enabling individuals to make informed health decisions throughout their lives while maintaining data privacy and security.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2017
- Employees
- 48
- Website
- myome.com/
- Ownership
- Privately Held (backing)
MyOme doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MyOme shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MyOme in its N-PORT filings yet. We sweep new filings monthly.